GLP1_NEW
Exenatide and dapagliflozin 10 to 10 µg injection twice daily
DAPAEXEN_SC_10-10UG_BID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 41.71) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.32 (0.00 to 10.40) | 0.72 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.01 to 46.70) | 0.56 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.67 (0.01 to 42.78) | 0.55 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 6.85 (0.26 to 190) | 0.22 |